Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Translate Bio	C4 Therapeutics	AlloVir	Replimune Group	REGENXBIO
Symbol	NASDAQ:TBIO	NASDAQ:CCCC	NASDAQ:ALVR	NASDAQ:REPL	NASDAQ:RGNX
Price Information
Current Price	$18.53	$33.20	$22.02	$34.79	$34.21
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.6	1.4	1.5	1.5	1.6
Analysis Score	4.3	3.5	3.5	3.5	3.4
Community Score	1.8	3.1	3.3	2.4	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	0.0	1.7	1.7
Earnings & Valuation Score	0.0	0.6	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$25.70	$44.50	$49.25	$56.00	$62.50
% Upside from Price Target	38.69% upside	34.04% upside	123.66% upside	60.97% upside	82.70% upside
Trade Information
Market Cap	$1.64 billion	$1.41 billion	$1.42 billion	$1.65 billion	$1.38 billion
Beta	0.96	N/A	N/A	2.63	1.28
Average Volume	1,179,664	275,756	345,595	384,831	425,652
Sales & Book Value
Annual Revenue	$7.80 million	N/A	N/A	N/A	$35.23 million
Price / Sales	178.72	N/A	N/A	N/A	41.27
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$2.56 per share	N/A	N/A	$5.01 per share	$12.23 per share
Price / Book	7.24	N/A	N/A	N/A	2.80
Profitability
Net Income	$-113,290,000.00	N/A	N/A	$-52,630,000.00	$-94,730,000.00
EPS	($1.84)	N/A	N/A	($1.54)	($3.26)
Trailing P/E Ratio	N/A	0.00	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-70.38%	N/A	N/A	N/A	-63.13%
Return on Equity (ROE)	-27.54%	N/A	N/A	-30.23%	-21.73%
Return on Assets (ROA)	-12.82%	N/A	N/A	-24.66%	-18.74%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	0.13%	N/A
Current Ratio	5.73%	5.22%	28.40%	19.47%	6.08%
Quick Ratio	5.73%	5.22%	28.40%	19.47%	6.08%
Ownership Information
Institutional Ownership Percentage	92.90%	N/A	32.07%	55.79%	75.23%
Insider Ownership Percentage	12.30%	N/A	1.00%	50.90%	14.10%
Miscellaneous
Employees	122	99	53	122	257
Shares Outstanding	75.23 million	43.19 million	65.11 million	46.49 million	42.51 million
Next Earnings Date	5/6/2021 (Estimated)	6/10/2021 (Estimated)	5/13/2021 (Estimated)	6/2/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Regenxbio EPS beats by $0.02, misses on revenue - Seeking Alpha seekingalpha.com - May 6 at 3:17 AM
	Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance finance.yahoo.com - May 6 at 3:17 AM
	Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates finance.yahoo.com - May 6 at 3:17 AM
	Regenxbio Inc. (RGNX) Q1 2021 Earnings Call Transcript finance.yahoo.com - May 6 at 3:17 AM
	REGENXBIO Inc. (RGNX) CEO Ken Mills on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - May 5 at 10:17 PM
	Regenxbio: Q1 Earnings Snapshot - The Edwardsville Intelligencer theintelligencer.com - May 5 at 10:17 PM
	REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights - PRNewswire prnewswire.com - May 5 at 5:16 PM
	REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights finance.yahoo.com - May 5 at 5:16 PM
	Companies Like Replimune Group (NASDAQ:REPL) Can Afford To Invest In Growth - Nasdaq nasdaq.com - May 5 at 12:15 PM
	Buy Or Fear REGENXBIO Stock: RGNX's 19% Decline In A Year Despite Revenues Increasing 339% YoY Over The Last 4 Quarters Looks Like A Buying Opportunity. The stock has lost 21% since the end of 2018 due to unfavorable Changes In Its Total Revenues - Trefis dashboards.trefis.com - May 5 at 12:15 PM
	Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely? - Nasdaq nasdaq.com - May 5 at 1:43 AM
	(RGNX) - Preview: Regenxbio's Earnings - Benzinga benzinga.com - May 4 at 3:42 PM
	What Is The Ownership Structure Like For REGENXBIO Inc. (NASDAQ:RGNX)? - Nasdaq nasdaq.com - May 4 at 3:42 PM
	Global Hunter Syndrome Treatment Market 2025: Top Key Players GC Pharma, Takeda Pharmaceutical Company, RegenxBio Inc. and others – FLA News - FLA News flanewsonline.com - May 4 at 5:41 AM
	Optogenetic Market By Size, Share, Trends, Forecast Analysis & Manufacturers – Addgene, Cobalt International Energy, Coherent, Laser Glow Technology, Jackson Laboratories, Regenxbio, Thorlabs – Clark County Blog - Clark County Blog clarkcountyblog.com - May 3 at 10:46 PM
	Adverum halt raises more gene therapy questions - Vantage evaluate.com - April 29 at 12:53 PM
	REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights - Yahoo Finance finance.yahoo.com - April 29 at 7:53 AM
	REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights finance.yahoo.com - April 29 at 1:21 AM
	REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights - Herald-Mail Media heraldmailmedia.com - April 28 at 8:21 PM
	REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting - PRNewswire prnewswire.com - April 27 at 11:13 PM
	REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting - Yahoo Finance finance.yahoo.com - April 27 at 6:13 PM
	REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting finance.yahoo.com - April 27 at 6:12 PM
	Metachromatic Leukodystrophy (MLD) Treatment Market Analysis, Market Size, Competitive Strategies, Forecasts to 2026 and Key Vendors: ArmaGen Inc, RegenxBio Inc, GlaxoSmithKline Plc, Recursion Pharmaceuticals Inc, More - Clark County Blog clarkcountyblog.com - April 27 at 8:12 AM
	Vaccines made from aborted fetus cells? Fargo firm aims to develop cell lines free of ethical concerns - West Central Tribune wctrib.com - April 22 at 1:33 PM
	Head to Head Analysis: REGENXBIO (NASDAQ:RGNX) & SQZ Biotechnologies (NYSE:SQZ) americanbankingnews.com - April 21 at 8:20 PM

Date	Company	Brokerage	Action
3/29/2021	Translate Bio	SVB Leerink	Reiterated Rating
3/24/2021	Translate Bio	Truist Securities	Reiterated Rating
3/24/2021	Translate Bio	Evercore ISI	Reiterated Rating
3/24/2021	Translate Bio	HC Wainwright	Lower Price Target
3/24/2021	Translate Bio	Roth Capital	Lower Price Target
3/19/2021	Translate Bio	William Blair	Reiterated Rating
10/5/2020	Translate Bio	The Goldman Sachs Group	Initiated Coverage
8/19/2020	Translate Bio	Citigroup	Lower Price Target
6/26/2020	Translate Bio	SunTrust Banks	Initiated Coverage
6/23/2020	Translate Bio	Jefferies Financial Group	Boost Price Target
3/31/2021	C4 Therapeutics	BMO Capital Markets	Initiated Coverage
10/28/2020	C4 Therapeutics	UBS Group	Initiated Coverage
4/26/2021	AlloVir	Morgan Stanley	Boost Price Target
2/11/2021	AlloVir	Piper Sandler	Boost Price Target
8/24/2020	AlloVir	JPMorgan Chase & Co.	Initiated Coverage
1/7/2019	AlloVir	Bank of America	Upgrade
11/17/2020	Replimune Group	BTIG Research	Initiated Coverage
10/15/2020	Replimune Group	Barclays	Boost Price Target
10/14/2020	Replimune Group	Chardan Capital	Boost Price Target
6/3/2020	Replimune Group	Wedbush	Reiterated Rating
1/20/2021	REGENXBIO	Royal Bank of Canada	Boost Price Target
1/6/2021	REGENXBIO	Raymond James	Upgrade

(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources